Baylor Scott & White Medical Center

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Ovarian cancer2 trials
• Bladder cancer1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Glioblastoma1 trial
• Liver and biliary tract cancer1 trial
• Pancreatic cancer1 trial
• Polycystic ovary syndrome1 trial
• Thyroid cancer1 trial

Phase

• Phase 23 trials
• Phase 31 trial

Status

• Completed3 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Fore Biotherapeutics1 trial
• Kyntra Bio1 trial
• Laekna Limited1 trial
• May Health1 trial
• NovoCure Ltd.1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

  Contact: North America Clinical Trial Support Desk

• Recruiting

  A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Phase 2· Fore Biotherapeutics· Source

  Contact: Jessica Rine

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Ovarian cancer1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Terminated

  The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

  NCT06206746· May Health· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Laekna Limited· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source